# Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

> **NCT01220141** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 51 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A
- Haemophilia B

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT01220141
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220141, "Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01220141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*